Whole-genome sequencing identifies responders to Pembrolizumab in relapse/refractory natural-killer/T cell lymphoma

Leukemia. 2020 Dec;34(12):3413-3419. doi: 10.1038/s41375-020-1000-0. Epub 2020 Aug 5.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Female
  • Humans
  • Killer Cells, Natural / drug effects*
  • Lymphoma, T-Cell / drug therapy*
  • Lymphoma, T-Cell / genetics*
  • Male
  • Middle Aged
  • Neoplasm Recurrence, Local / drug therapy*
  • Neoplasm Recurrence, Local / genetics*
  • Whole Genome Sequencing / methods

Substances

  • Antibodies, Monoclonal, Humanized
  • pembrolizumab